T. Rowe Price Associates
ADVM

T. Rowe Price Associates’s Adverum Biotechnologies ADVM Stock Holding History

T. Rowe Price Associates’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,410
Closed -$117K – 2976
2021
Q3 		$117K Hold
5,410
– – ﹤0.01% 2818
2021
Q2 		$189K Sell
5,410
-52,483
-91% -$2.83M ﹤0.01% 2740
2021
Q1 		$5.71M Sell
57,893
-107,850
-65% -$12.9M ﹤0.01% 1454
2020
Q4 		$18M Buy
165,743
+60,230
+57% +$7.45M ﹤0.01% 1245
2020
Q3 		$10.9M Sell
105,513
-106,952
-50% -$16M ﹤0.01% 1282
2020
Q2 		$44.4M Sell
212,465
-32,872
-13% -$5.82M 0.01% 885
2020
Q1 		$24M Buy
245,337
+120,158
+96% +$14M ﹤0.01% 1012
2019
Q4 		$14.4M Buy
125,179
+20,569
+20% +$1.81M ﹤0.01% 1248
2019
Q3 		$5.7M Buy
104,610
+48,806
+87% +$5.5M ﹤0.01% 1367
2019
Q2 		$6.63M Buy
+55,804
New +$4.62M ﹤0.01% 1365
2015
Q2 		– Sell
-52,658
Closed -$21.3M – 2538
2015
Q1 		$21.3M Sell
52,658
-49,887
-49% -$21.1M ﹤0.01% 1110
2014
Q4 		$53.7M Sell
102,545
-730
-0.7% -$281K 0.01% 814
2014
Q3 		$34.2M Buy
+103,275
New +$30.7M 0.01% 954

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

T. Rowe Price Associates's ADVM Position: Q4 2021 in Review

T. Rowe Price Associates sold out of Adverum Biotechnologies (ADVM) in Q4 2021, closing a stake of 5,410 shares — an estimated $117K sold.

T. Rowe Price Associates first reported a position in ADVM in Q3 2014 and held it in 13 quarters. The position peaked at $53.7M in Q4 2014. 98 funds tracked by Wall St. Rank hold ADVM as of Q4 2021.

  • T. Rowe Price Associates reported no remaining Adverum Biotechnologies position as of Q4 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 5,410 Adverum Biotechnologies shares in Q4 2021, an estimated $117K.
  • T. Rowe Price Associates first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 13 quarters.
  • T. Rowe Price Associates's Adverum Biotechnologies position peaked at $53.7M in Q4 2014.
  • 98 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2021.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.